Immunotherapy in lung cancer

Published on November 28, 2019   37 min

Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms

0:00
Hello. My name is Mark Awad. I'm the Clinical Director for the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, and assistant professor at Harvard Medical School. I'll be discussing updates on immunotherapy for treatment of lung cancer.
0:19
This is an outline of our topics for discussion today. We'll be discussing the role of immunotherapy in non-small cell lung cancer, both for stage four disease as well as unresectable stage three, surgically resectable, non-small cell lung cancer. We'll discuss a bit about some emerging data in small-cell lung cancer.
0:41
So to start, we'll talk about stage four non-small cell lung cancer where the first approvals of immunotherapy occurred.
0:49
There have been a number of rapid developments in immuno-oncology non-small cell lung cancer over the past few years. Before 2015, the standard of care for non-small cell lung cancer was to use first-line platinum doublet chemotherapy followed by a second line docetaxel. Typically after that point, patients would be referred for best supportive care.
1:12
Our previous standard second line therapy docetaxel has a low response rate typically of around seven percent. But this was the standard of care from the year early 2000s up until about 2015.